Abstract
Dupilumab is a monoclonal antibody approved for the treatment of atopic dermatitis (AD) and asthma. However, adverse ocular surface reactions often arise as side effects– conjunctivitis has been reported in 16% of patients. We report the use of dupilumab in a patient with AD, asthma and atopic keratoconjunctivitis (AKC) resulting in improvement in all three conditions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
